Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

89.70 +3.43 (+3.98%)
Streaming Delayed Price Updated: 10:58 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Tempus to Participate in the Stifel 2025 Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2025 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
From Ambry Genetics
Via Business Wire
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
From Tempus AI, Inc.
Via Business Wire
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
From Tempus AI, Inc.
Via Business Wire
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
From Ambry Genetics
Via Business Wire
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
From Tempus AI, Inc.
Via Business Wire
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
From Tempus AI, Inc.
Via Business Wire
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
From Tempus AI, Inc.
Via Business Wire
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
From Tempus AI, Inc.
Via Business Wire
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tempus Announces the Acquisition of Paige
From Tempus AI, Inc.
Via Business Wire
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TEMPUS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Tempus Investors of the August 11th Deadline and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
From Pomerantz LLP
Via GlobeNewswire
TEMPUS AI 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
From Kahn Swick & Foti, LLC
Via Business Wire
Deadline Soon: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
Tempus Reports Second Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
From SkyMedia, LLC
Via GlobeNewswire
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
From Kahn Swick & Foti, LLC
Via GlobeNewswire
TEMPUS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
From Pomerantz LLP
Via GlobeNewswire
TEMPUS AI, INC. (NASDAQ: TEM) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Tempus AI, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
From Pomerantz LLP
Via GlobeNewswire
TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
From SkyMedia, LLC
Via GlobeNewswire
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis and Tempus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.